logo-loader
viewQ BioMed Inc.

Q BioMed partners with SRI International to push potentially multi-bn product toward clinical trials

Q BioMed Inc (OTCQB:QBIO) Denis Corin tells Proactive Investors the biopharma company has announced a partnership with non-profit scientific research company SRI International to provide formulation development, pre-clinical development and clinical manufacturing of QBM-001 to treat non-verbal autistic children.

Corin says the economics around the drug are significant; there are 50,000 patients around the world and the average orphan price drug is in the hundreds of thousands of dollars.

Quick facts: Q BioMed Inc.

Price: 1.85 USD

OTCQB:QBIO
Market: OTCQB
Market Cap: $41.57 m
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

In exchange for publishing services rendered by the Company on behalf of Q BioMed Inc. named herein, including the promotion by the Company of Q BioMed Inc. in any Content on the Site, the Company receives from said...

FOR OUR FULL DISCLAIMER CLICK HERE

Watch

Q BioMed activates its marketing campaign for its cancer bone pain drug

Q BioMed Inc (OTCQB:QBIO) Chief Commercialization Officer Kristin Keller tells Proactive the New York-based biotechnology firm has launched a marketing campaign for its non-opioid cancer bone pain drug Strontium89. Keller says the company has created a product website at Strontium89.com to...

on 05/20/2020

2 min read